New Global Study Will Assess Lower Booster Doses As Vaccine-Sparing Measure
In the run-up to a major pandemic preparedness summit in London next month, CEPI has announced a new trial aimed at broadening access to vaccines in lower-income countries and has welcomed fresh funding for its plan to cut vaccine development times to 100 days.
You may also be interested in...
Is a 100-day timeline for developing vaccines against newly identified health threats a realistic proposition? Attendees at this week’s Global Pandemic Preparedness Summit certainly think so. Meanwhile, Moderna has said it will build its first African mRNA plant in Kenya, and has pledged “never” to enforce its vaccine patents in lower-income countries.
The process of drafting an international agreement on pandemic preparedness and response is picking up speed, although one NGO has warned that this must not distract from more immediate priorities such as technology transfer for producing COVID-19 medical products.
The World Health Organization is ramping up its efforts to provide lower-income countries with the ability to produce their own biological products, such as vaccines and monoclonal antibodies. A new biomanufacturing training facility is in the works, and more recipients of mRNA technology transfer for vaccine production are being chosen.